Vistagen Therapeutics, Inc. (VTGN)
0.1706
0.00 (0.00%)
USD |
NASDAQ |
Oct 29, 16:00
0.1706
0.00 (0.00%)
After-Hours: 20:00
Vistagen Therapeutics Enterprise Value : -23.40M for Oct. 28, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 28, 2026 | -23.40M |
| October 27, 2026 | -23.22M |
| October 26, 2026 | -23.23M |
| October 23, 2026 | -22.97M |
| October 22, 2026 | -22.65M |
| October 21, 2026 | -22.35M |
| October 20, 2026 | -22.17M |
| October 19, 2026 | -21.93M |
| October 16, 2026 | -22.07M |
| October 15, 2026 | -21.49M |
| October 14, 2026 | -21.78M |
| October 13, 2026 | -21.41M |
| October 12, 2026 | -20.89M |
| October 09, 2026 | -20.47M |
| October 08, 2026 | -20.02M |
| October 07, 2026 | -19.98M |
| October 06, 2026 | -19.82M |
| October 05, 2026 | -19.27M |
| October 02, 2026 | -18.48M |
| October 01, 2026 | -18.40M |
| September 30, 2026 | -17.29M |
| September 29, 2026 | -17.72M |
| September 28, 2026 | -17.77M |
| September 25, 2026 | -18.83M |
| September 24, 2026 | -17.85M |
| Date | Value |
|---|---|
| September 23, 2026 | -14.60M |
| September 22, 2026 | -19.79M |
| September 21, 2026 | -20.61M |
| September 18, 2026 | -20.30M |
| September 17, 2026 | -20.58M |
| September 16, 2026 | -20.71M |
| September 15, 2026 | -20.47M |
| September 14, 2026 | -20.15M |
| September 11, 2026 | -20.43M |
| September 10, 2026 | -20.34M |
| September 09, 2026 | -20.50M |
| September 08, 2026 | -20.14M |
| September 04, 2026 | -20.17M |
| September 03, 2026 | -20.02M |
| September 02, 2026 | -20.03M |
| September 01, 2026 | -20.15M |
| August 31, 2026 | -19.63M |
| August 28, 2026 | -19.72M |
| August 27, 2026 | -19.54M |
| August 26, 2026 | -19.41M |
| August 25, 2026 | -19.92M |
| August 24, 2026 | -20.13M |
| August 21, 2026 | -20.12M |
| August 20, 2026 | -20.25M |
| August 19, 2026 | -20.11M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Onconetix, Inc. | -3.485M |
| ACADIA Pharmaceuticals, Inc. | 2.615B |
| Alnylam Pharmaceuticals, Inc. | 30.76B |
| Anika Therapeutics, Inc. | 275.24M |
| Savara, Inc. | 888.48M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -13.03M |
| Revenue (Quarterly) | 1.476M |
| Total Expenses (Quarterly) | 14.51M |
| EPS Diluted (Quarterly) | -0.3032 |
| Gross Profit Margin (Quarterly) | 86.65% |
| Profit Margin (Quarterly) | -882.8% |
| Earnings Yield | -999.2% |
| Normalized Earnings Yield | -999.12 |